TMG Investigators Dr. Peter Dzongowski, Dr. Michael Jones, and Dr. Sean Peterson were all recently involved in the GSK trial AReSVi 006, evaluating a vaccine candidate for Respiratory Syncytial Virus (RSV). Recruitment was highly successful for all three investigators, whose work has helped lead to the first RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above.
RSV is a common contagious virus affecting the lungs and breathing passages. It is one of the major remaining infectious diseases for which there is currently no vaccine or specific treatment. Older adults are at high risk for severe disease due to age-related decline in immunity and underlying conditions.
Results from this phase 3 trial will be presented in a peer-reviewed publication at an upcoming scientific meeting. This trial will continue to evaluate both an annual revaccination schedule and longer-term protection over multiple seasons following one dose of the older adult (OA) vaccine candidate.
“These data suggest our RSV vaccine candidate offers exceptional protection for older adults from the serious consequences of RSV infection. RSV remains one of the few major infectious diseases without a vaccine, and these data have the potential to meaningfully impact the treatment of RSV and may reduce the 360,000 hospitalizations and more than 24,000 deaths worldwide each year. Given the importance of these data, we plan to engage with regulators immediately and anticipate regulatory submissions in the second half of 2022,” stated Dr Hal Barron, Chief Scientific Officer and President of Research and Development at GSK.
To read the official press release from GSK, please click here.